Navigation Links
Particle Sciences Acquires Exclusive License to Lyotropic Therapeutics' Drug Delivery Technology
Date:3/5/2012

BETHLEHEM, Pa., March 5, 2012 /PRNewswire/ -- Particle Sciences, Inc. (PSI), a leading pharmaceutical CRO, and Lyotropic Therapeutics, Inc. (LTI), a drug delivery technology company, announced today that Particle Sciences has acquired the exclusive rights to Lyotropic's LyoCell® patent portfolio.  The LyoCell technology allows for the solubilization, stabilization, and delivery of a wide range of compounds - both small and large molecule.  According to Robert Lee, Particle Sciences' VP Pharmaceutical Development, "LyoCells are proprietary lyotropic liquid crystal-based formulations that contain both polar and non-polar nano-domains.  These unique structures create ideal conditions for the solubilization and stabilization of many pharmaceuticals and biopharmaceuticals.  Made from GRAS ingredients, this technology is already in late stage clinical development in an intravenous product and has applications in most routes of administration."  Under the revenue-share agreement, PSI obtains a full license to the technology except for several compounds previously developed by LTI.  Particle Sciences will offer the technology to its clients looking to increase bioavailability or develop parenteral formulations of difficult-to-solubilize compounds. Intellectual property around the stabilization of macromolecules is also included in the transaction. 

Vince Conklin, Lyotropic Therapeutics' CEO, adds that, "The LyoCell technology has proven to be highly effective in solving very difficult formulation problems and is the basis for several drugs now in or poised to enter the clinical stage. We are very pleased to have a partner like Particle Sciences, a leader in the formulation and drug delivery space, who is well positioned to further broaden exposure for the LyoCell technology and to employ its enormous utility." 

Rob Lee adds, "The technology is protected by a family of very young patents offering protection to 2028 and beyond. Particle Sciences is very excited to bring the technology to our clients as it addresses the top technical issues we face every day, namely solubility and bioavailability, while also providing solid patent protection.  Lyotropic liquid crystals has proven to be an outstanding approach that utilizes GRAS ingredients, something very unusual today.  We anticipate our clients using this for both new chemical entities as well as life-cycle extension efforts.  In both situations, the LyoCell technology has a lot to offer."

Particle Sciences is an integrated provider of drug development services.  Particle Sciences focuses on emulsions, gels, micro and nano-particulates, drug/device combination products and highly potent compounds across all dosage forms. Through a full range of formulation, analytic, and manufacturing services, Particle Sciences provides pharmaceutical companies with a complete and seamless development solution that minimizes the time and risk between discovery and the clinic.  The company was founded in 1991 and is headquartered in Bethlehem, Pennsylvania.  Visit www.particlesciences.com, email info@particlesciences.com or contact us at (610) 861- 4701 for information.

Lyotropic Therapeutics, based in Richmond, Virginia, is a privately held company formed in 1999 to develop and commercialize the LyoCell® and other drug delivery technologies.  The Company's mission is to develop drug delivery formulations across a broad range of product applications with a special emphasis on therapies for critical care, anesthesia and pain management.

Contact:
Maureen Mattera
610.861.4701
mmattera@particlesciences.com


'/>"/>
SOURCE Particle Sciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. American Regent Initiates Nationwide Voluntary Recall of Phenylephrine HCl Injection, USP, 1%, 5 mL Vial, Lot# 0693, Due to Visible Particles
2. Particle Sciences Hires Robert Gwozdz to Head Oral Formulation
3. Brabender® Pharma USA, Inc. and Particle Sciences Cooperate to Expand Extrusion Capabilities
4. Particle Sciences Expands Its DOSE™ Program With Additional Proprietary Modeling Capabilities
5. Particle Sciences Granted Patent on Self Sterilizing Medical Devices
6. Particle Sciences and Absorption Systems Form Relationship to Offer their Clients Enhanced Services
7. Particle Sciences Develops Proprietary Nasal Delivery Formulation Used in Neurelis Recently Announced Successful Phase I Pharmacokinetic Study of NRL-01 (intranasal diazepam)
8. Pearl Therapeutics Highlights Its Porous Particle Cosuspension Platform, Demonstrating Universal Applicability Across Multiple Drug Classes and Combination Products
9. Particle Sciences and Celanese EVA Performance Polymers Collaborate to Accelerate Drug-Eluting Device Combinations
10. American Regent Initiates Nationwide Voluntary Recall of Potassium Phosphates Injection, USP, 15 mM/5 mL Phosphorus; 22 mEq/5 mL Potassium, 5 mL Single Dose Vial, Lot # 0048 Due to Translucent Visible Particles
11. IBA Particle Therapys $20,000 Grant Helps Non-Profit Ease Costs for Children Traveling to Receive Proton Therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... Feb. 5, 2016 Aethlon Medical, Inc. (Nasdaq: ... and CEO, will be presenting at Source Capital Group,s 2016 ... NY at 2:15 p.m. ET on Wednesday, February ... Panel discussion taking place at 3:15 p.m. ET. ... one hour after the conclusion of the live event. The ...
(Date:2/5/2016)... , February 5, 2016 ... Market Research report states that the global active pharmaceuticals ... and is predicted to reach US$185.9 bn by 2020. ... 6.50% from 2014 to 2020. The title of the ... Captive/Contract Manufactured, by Geography, and by Therapeutic Area) - ...
(Date:2/5/2016)... , Feb. 5, 2016  Zimmer Biomet Holdings, Inc. ... the previously announced underwritten secondary offering of 11,027,558 shares ... consisting of affiliates of Blackstone and Goldman Sachs.  The ... initial price of $96.45 per share. The selling stockholders ...  Neither Zimmer Biomet nor any of its directors, officers ...
Breaking Medicine Technology:
(Date:2/5/2016)... ... 05, 2016 , ... Francisco Canales, MD and Heather Furnas, ... Valley office. The technique utilizes the body’s own healing abilities to quickly rejuvenate ... are part of only a select few cosmetic surgeons bringing this procedure to ...
(Date:2/5/2016)... ... February 05, 2016 , ... After years as an active ... Unit, plastic and cosmetic surgeon Dr. Wayne Carman transitioned to chief of the Division ... completed his first three-year term as chief and began a second three-year term in ...
(Date:2/5/2016)... , ... February 05, 2016 , ... ... PROSHRED franchises from across the country gathered at the La Valencia Hotel in ... performers. PROSHRED Chicago was named the year’s most outstanding franchise, walking away ...
(Date:2/5/2016)... ... 05, 2016 , ... Give To Cure today announced that it ... to Give To Cure’s campaign that is crowdfunding clinical trials to help find cures ... payments through a smart device. In 2015 alone, Venmo processed $7.5 billion in transactions ...
(Date:2/5/2016)... ... February 05, 2016 , ... At its annual meeting held ... as Chairman of the National Board of Directors. Mr. McDermott succeeds former APDA Chairman, ... stated Leslie A. Chambers , APDA President and CEO. “Pat has tirelessly served ...
Breaking Medicine News(10 mins):